A detailed history of Simplex Trading, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Simplex Trading, LLC holds 178 shares of FATE stock, worth $359. This represents 0.0% of its overall portfolio holdings.

Number of Shares
178
Previous 1,482 87.99%
Holding current value
$359
Previous $4,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$3.12 - $5.57 $4,068 - $7,263
-1,304 Reduced 87.99%
178 $0
Q2 2024

Jul 25, 2024

SELL
$3.26 - $7.08 $449 - $977
-138 Reduced 8.52%
1,482 $4,000
Q1 2024

Apr 25, 2024

BUY
$3.54 - $8.35 $605 - $1,427
171 Added 11.8%
1,620 $11,000
Q4 2023

Feb 02, 2024

BUY
$1.65 - $3.94 $1,864 - $4,452
1,130 Added 354.23%
1,449 $5,000
Q3 2023

Nov 01, 2023

SELL
$2.02 - $5.04 $18,426 - $45,974
-9,122 Reduced 96.62%
319 $0
Q2 2023

Aug 04, 2023

SELL
$4.76 - $6.59 $4,260 - $5,898
-895 Reduced 8.66%
9,441 $44,000
Q1 2023

Apr 27, 2023

BUY
$4.24 - $11.12 $37,447 - $98,211
8,832 Added 587.23%
10,336 $58,000
Q4 2022

Feb 02, 2023

BUY
$9.86 - $23.83 $1,370 - $3,312
139 Added 10.18%
1,504 $15,000
Q3 2022

Nov 04, 2022

BUY
$21.04 - $36.06 $25,079 - $42,983
1,192 Added 689.02%
1,365 $30,000
Q2 2022

Aug 03, 2022

SELL
$17.78 - $42.39 $182,138 - $434,243
-10,244 Reduced 98.34%
173 $4,000
Q1 2022

May 02, 2022

BUY
$29.67 - $60.28 $296,432 - $602,257
9,991 Added 2345.31%
10,417 $403,000
Q4 2021

Feb 23, 2022

BUY
$47.84 - $64.34 $20,379 - $27,408
426 New
426 $24,000
Q4 2020

Feb 02, 2021

SELL
$38.09 - $100.95 $734,527 - $1.95 Million
-19,284 Closed
0 $0
Q3 2020

Oct 14, 2020

BUY
$30.41 - $40.5 $586,426 - $781,002
19,284 New
19,284 $770,000
Q1 2020

Apr 29, 2020

SELL
$17.28 - $31.88 $27,285 - $50,338
-1,579 Closed
0 $0
Q4 2019

Feb 05, 2020

SELL
$13.39 - $20.73 $117,952 - $182,610
-8,809 Reduced 84.8%
1,579 $30,000
Q3 2019

Oct 15, 2019

SELL
$15.47 - $22.5 $5,290 - $7,695
-342 Reduced 3.19%
10,388 $161,000
Q2 2019

Jul 26, 2019

SELL
$15.61 - $20.44 $119,931 - $157,040
-7,683 Reduced 41.73%
10,730 $217,000
Q1 2019

Apr 18, 2019

BUY
$13.15 - $18.71 $131,749 - $187,455
10,019 Added 119.36%
18,413 $0
Q4 2018

Jan 16, 2019

BUY
$11.48 - $16.98 $95,054 - $140,594
8,280 Added 7263.16%
8,394 $107,000
Q3 2018

Oct 23, 2018

SELL
$8.75 - $16.29 $114,196 - $212,600
-13,051 Reduced 99.13%
114 $1,000
Q2 2018

Jul 30, 2018

SELL
$9.16 - $13.48 $149,280 - $219,683
-16,297 Reduced 55.32%
13,165 $149,000
Q1 2018

Apr 26, 2018

BUY
$6.3 - $13.77 $160,448 - $350,694
25,468 Added 637.66%
29,462 $287,000
Q4 2017

Jan 10, 2018

BUY
$3.94 - $6.64 $15,326 - $25,829
3,890 Added 3740.38%
3,994 $24,000
Q3 2017

Oct 25, 2017

BUY
$2.6 - $4.31 $270 - $448
104
104 $0

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $196M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.